Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 5
---
 | Per        
 Pre-Funded 
 Unit       |     |   | Total |
|:---------------------------------|:----|:--|:-----|:----|:--|:-----------|:----|:--|:------|
| Public offering price            |     | $ |      |     | $ |            |     | $ |       |
| Placement agent fees(1)          |     | $ |      |     | $ |            |     | $ |       |
| Proceeds, before expenses, to us |     | $ |      |     | $ |            |     | $ |       |

________

| (1) | We                                                                                           
 will pay the placement agent a cash fee equal to 7.0% of the aggregate gross proceeds raised 
 in this offering. In addition, we have agreed to reimburse the placement agent for certain   
 offering-related expenses, to sell to the placement agent warrants, or the Placement Agent   
 Warrants, to purchase up to a number of Depositary Shares equal to 5.0% of the aggregate     
 number of Units and Pre-Funded Units being offered hereby at a purchase price equal to the   
 aggregate nominal value of the Ordinary Shares underlying the Placement Agent Warrants, or   
 the Nominal Value Amount, and to pay a fee to the placement agent equal to the Nominal Value 
 Amount. The Placement Agent Warrants and the Depositary Shares issuable upon exercise of     
 the Placement Agent Warrants are also being registered under the registration statement of   
 which this prospectus forms a part. We refer you to “Plan of Distribution” for               
 additional information regarding placement agent compensation.                               |

We are a “foreign private issuer,” as defined in the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are exempt from certain rules under the Exchange Act that impose certain disclosure obligations and procedural requirements for proxy solicitations under Section 14 of the Exchange Act. In addition, our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions under Section 16 of the Exchange Act. Moreover, we are not required to file periodic reports and financial statements with the Securities and Exchange Commission as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.

As a foreign private issuer, we have elected to follow home country practice instead of complying with NASDAQ Listing Rule 5635(d) shareholder approval requirements, we are not required to obtain, and do not intend to seek, shareholder